Axogen Appoints New CMO, Director; Discloses Executive Pay

Ticker: AXGN · Form: 8-K · Filed: Mar 8, 2024 · CIK: 805928

Axogen, Inc. 8-K Filing Summary
FieldDetail
CompanyAxogen, Inc. (AXGN)
Form Type8-K
Filed DateMar 8, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $9,079.16, $75,000, $228,385
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, board-appointment, executive-compensation

Related Tickers: AXGN

TL;DR

Axogen brings in a new CMO and board member, and details exec pay.

AI Summary

Axogen, Inc. announced on March 7, 2024, the appointment of Dr. Steven J. Hanley as Chief Medical Officer and the election of Ms. Karen L. King to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers. These changes are effective immediately.

Why It Matters

The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts or a focus on specific areas within the company's operations and governance.

Risk Assessment

Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

  • Axogen, Inc. (company) — Registrant
  • Dr. Steven J. Hanley (person) — Appointed Chief Medical Officer
  • Ms. Karen L. King (person) — Elected to Board of Directors
  • March 7, 2024 (date) — Effective date of appointments and disclosures

FAQ

Who has been appointed as the new Chief Medical Officer of Axogen, Inc.?

Dr. Steven J. Hanley has been appointed as the new Chief Medical Officer of Axogen, Inc.

Who has been elected to the Board of Directors of Axogen, Inc.?

Ms. Karen L. King has been elected to the Board of Directors of Axogen, Inc.

What is the effective date of the reported changes?

The earliest event reported is dated March 7, 2024.

What other information is disclosed in this 8-K filing?

The filing also discloses compensatory arrangements for certain officers.

What is Axogen, Inc.'s state of incorporation?

Axogen, Inc. is incorporated in Minnesota.

Filing Stats: 789 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-03-08 16:38:31

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market
  • $9,079.16 — be eligible to receive a monthly fee of $9,079.16 per month. If Mr. Scopelianos provides
  • $75,000 — led to a one-time additional payment of $75,000. Pursuant to the terms of the Transiti
  • $228,385 — be entitled to his 2023 bonus amount of $228,385.26, which will be paid out on March 15,

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits See the Exhibit index below, which is incorporated herein by reference. Exhibit No. Description 10.1 Transition and Separation Agreement, dated March 7, 2024 , between the Company and Angelo Scopelianos 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: March 7, 2024 By: Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.